REVTx-300 leads to significant reductions in renal cortical fibrosis in preclinical model of AKI

Oct. 26, 2022

Revelation Biosciences Inc. announced positive results for REVTx-300 in a preclinical model of acute kidney injury (AKI), a type of chronic kidney disease (CKD).

BioWorld Science Nephrology

Today's news in brief

BioWorld

BioWorld briefs for May 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 13, 2025.

Little bite from voluntary most-favored nation Rx pricing order

BioWorld

After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...

AI generated, 3D rendering of protein degradation

AACR 2025: Induced proximity strategy, beyond degraders

BioWorld

Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...

China’s NMPA gives thumbs up to Remegen’s ADC targeting HER2

BioWorld

China’s National Medical Products Administration has approved Remegen Co. Ltd.’s antibody-drug conjugate (ADC), disitamab vedotin (RC-48), for treatment of...